Novartis FDA approves Rhapsido for symptomatic dermographism
The FDA approved Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism, expanding its use beyond chronic spontaneous urticaria (CSU).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.